Printer Friendly

ONCOR RECEIVES FDA MARKET APPROVAL ON SECOND GENERATION DNA-BASED TEST FOR DETECTION & MONITORING OF LEUKEMIA & LYMPHOMA

 ONCOR RECEIVES FDA MARKET APPROVAL ON SECOND GENERATION
 DNA-BASED TEST FOR DETECTION & MONITORING OF LEUKEMIA & LYMPHOMA
 GAITHERSBURG, Md., Feb. 10 /PRNewswire/ -- Oncor, Inc. (NASDAQ: ONCR), a leading manufacturer and marketer of DNA probe-based test systems for the diagnosis, monitoring and management of cancer and other genetic diseases, has met U.S. Food and Drug Administration (FDA) Premarket Approval requirements to distribute an improved version of its B/TGene Rearrangement Test System for use in the diagnosis and monitoring of leukemia and lymphoma, Stephen Turner, Oncor's chairman and chief executive officer, announced today.
 "Oncor's second generation B/T Test System, to be marketed under the trade name 'B/T Blue,' is superior to our existing system in several ways. It employs non-isotopic (non-radioactive) DNA probes and a proprietary DNA extraction chemistry, two major advances which eliminate hazardous materials and reduce patient result time to four days from the current seven days."
 In October 1989, Oncor received FDA market approval for its earlier version B/T Test System for leukemia and lymphoma.
 Said Turner: "The approval by the FDA of Oncor's improved B/T Test System is further evidence of Oncor's commitment to maintaining its leadership position in the development and marketing of DNA-based cancer diagnostics. Oncor's B/T Test System, which is currently in use in more than 100 laboratories in the U.S., has been widely accepted and is well on its way to becoming a core test in laboratories performing cancer diagnosis. The test can be used to analyze the 85,000 new cases of leukemia and lymphoma diagnosed annually in the U.S. and to monitor the 330,000 or more patients who have suffered from leukemia and lymphoma and who are at risk of recurrence.
 -0- 2/10/92
 /CONTACT: Stephen Turner, chairman & CEO of Oncor, 301-963-3500/
 (ONCR) CO: Oncor, Inc. ST: Maryland IN: MTC SU:


TS-JT -- NY024 -- 8170 02/10/92 09:47 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 10, 1992
Words:318
Previous Article:GENERAL ELECTRIC SELECTS UNITED HEALTHCARE'S UTILIZATION MANAGEMENT COMPANY
Next Article:CHARLESTON, S.C., INVESTMENT FIRM HEAD NAMED TO BOARD OF ONLY NATIONAL FARMLAND PROTECTION GROUP
Topics:


Related Articles
ONCOR AND UNIVERSITY OF UTAH TO DEVELOP GENETIC TESTS FOR PROSTATE CANCER
ONCOR, INCORPORATED ANNOUNCES EUROPEAN PARTNERSHIP WITH AMERSHAM INTERNATIONAL
ONCOR REPORTS RECORD SALES FOR FOURTH QUARTER AND FULL YEAR 1992
ONCOR ACQUIRES EXCLUSIVE LICENSES FOR DNA PROBES TO DETECT THE TELOMERES OF HUMAN CHROMOSOMES
ONCOR, INC. REPORTS OPERATING RESULTS FOR THIRD QUARTER AND NINE MONTHS OF 1993
ONCOR SUBMITS FDA APPLICATION FOR CHRONIC MYELOGENOUS LEUKEMIA GENETIC TEST SYSTEM
/C O R R E C T I O N -- ONCOR, INC./ (Correction Notice)
Digene Receives U.S. FDA Approval for Cytomegalovirus (CMV) Test.
American Cancer Society Publishes Cervical Cancer Screening Guidelines Supporting HPV Testing.
New Study in 'JAMA' Supports Use of Digene's HPV Test As Primary Cervical Cancer Screen.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters